GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Asset Turnover

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Asset Turnover : 0.06 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Alseres Pharmaceuticals's Revenue for the three months ended in Jun. 2014 was $0.02 Mil. Alseres Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2014 was $0.32 Mil. Therefore, Alseres Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2014 was 0.06.

Asset Turnover is linked to ROE % through Du Pont Formula. Alseres Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2014 was 11.89%. It is also linked to ROA % through Du Pont Formula. Alseres Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2014 was -399.38%.


Alseres Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Alseres Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Asset Turnover Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.93 0.70

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.13 1.60 0.05 0.06

Competitive Comparison of Alseres Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Alseres Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Asset Turnover falls into.



Alseres Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Alseres Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2013 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2013 )/( (Total Assets (A: Dec. 2012 )+Total Assets (A: Dec. 2013 ))/ count )
=0.474/( (0.966+0.385)/ 2 )
=0.474/0.6755
=0.70

Alseres Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2014 )/( (Total Assets (Q: Mar. 2014 )+Total Assets (Q: Jun. 2014 ))/ count )
=0.018/( (0.364+0.279)/ 2 )
=0.018/0.3215
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Alseres Pharmaceuticals  (OTCPK:ALSE) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Alseres Pharmaceuticals's annulized ROE % for the quarter that ended in Jun. 2014 is

ROE %**(Q: Jun. 2014 )
=Net Income/Total Stockholders Equity
=-1.284/-10.8005
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.284 / 0.072)*(0.072 / 0.3215)*(0.3215/ -10.8005)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1783.33 %*0.224*-0.0298
=ROA %*Equity Multiplier
=-399.38 %*-0.0298
=11.89 %

Note: The Net Income data used here is four times the quarterly (Jun. 2014) net income data. The Revenue data used here is four times the quarterly (Jun. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Alseres Pharmaceuticals's annulized ROA % for the quarter that ended in Jun. 2014 is

ROA %(Q: Jun. 2014 )
=Net Income/Total Assets
=-1.284/0.3215
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.284 / 0.072)*(0.072 / 0.3215)
=Net Margin %*Asset Turnover
=-1783.33 %*0.224
=-399.38 %

Note: The Net Income data used here is four times the quarterly (Jun. 2014) net income data. The Revenue data used here is four times the quarterly (Jun. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Alseres Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines